Organoid modeling of the tumor immune microenvironment

Published: 31 October 2018| Version 1 | DOI: 10.17632/ykpbxfx2p9.1
Contributor:
Calvin Kuo

Description

Supplemental information for "Organoid modeling of the tumor immune microenvironment", Neal et al., Cell. Please see manuscript for further information.

Files

Steps to reproduce

Human PDO culture 14 Tumor tissues were minced finely, washed twice in ADMEM/F12 (Invitrogen) containing 1X Normocin 15 (InvivoGen), resuspended in Type I collagen gel (Trevigen), and layered in a double dish air-liquid 16 culture system as previously described8. Organoids were cultured in human organoid medium 17 (ADMEM/F12 supplemented with 50% Wnt3a, RSPO1, Noggin-conditioned media (L-WRN, ATCC), 18 HEPES (1mM, Invitrogen), Glutamax (1X, Invitrogen), Nicotinamide (10 mM, Sigma), N-Acetylcysteine 19 (1 mM, Sigma), B-27 without vitamin A (1X, Invitrogen), A83-01 (0.5 μM, Tocris), Pen-Strep Glutamine 20 (1X, Invitrogen), Gastrin (10 nM, Sigma), SB-202190 (10 μM, Sigma), and EGF (50 ng/mL, Invitrogen). 21 Organoids were passaged every 14-30 days by dissociation with 200 units ml−1 collagenase IV 22 (Worthington) at 37 °C for 30 min, followed by three 5-min washes with 100% FBS and replating at a 23 1:4 split into new air-liquid interface collagen gels. Additionally, in some cases, media was 24 supplemented with recombinant human IL-2 (Peprotech) at 600 or 6000 IU/ml.

Categories

Cancer, Immunotherapy, Organoid

Licence